- Home
- CEE vs IOBT Comparison
CEE vs IOBT Comparison
Compare CEE & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- IOBT
- Stock Information
- Founded
- CEE 1990
- IOBT 2014
- Country
- CEE Germany
- IOBT Denmark
- Employees
- CEE N/A
- IOBT N/A
- Industry
- CEE Finance Companies
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- IOBT Health Care
- Exchange
- CEE Nasdaq
- IOBT Nasdaq
- Market Cap
- CEE 97.8M
- IOBT 79.7M
- IPO Year
- CEE N/A
- IOBT 2021
- Fundamental
- Price
- CEE $15.06
- IOBT $1.30
- Analyst Decision
- CEE
- IOBT Strong Buy
- Analyst Count
- CEE 0
- IOBT 3
- Target Price
- CEE N/A
- IOBT $9.33
- AVG Volume (30 Days)
- CEE 22.0K
- IOBT 235.8K
- Earning Date
- CEE 01-01-0001
- IOBT 08-12-2025
- Dividend Yield
- CEE 3.86%
- IOBT N/A
- EPS Growth
- CEE N/A
- IOBT N/A
- EPS
- CEE N/A
- IOBT N/A
- Revenue
- CEE N/A
- IOBT N/A
- Revenue This Year
- CEE N/A
- IOBT N/A
- Revenue Next Year
- CEE N/A
- IOBT N/A
- P/E Ratio
- CEE N/A
- IOBT N/A
- Revenue Growth
- CEE N/A
- IOBT N/A
- 52 Week Low
- CEE $7.80
- IOBT $0.66
- 52 Week High
- CEE $10.32
- IOBT $1.73
- Technical
- Relative Strength Index (RSI)
- CEE 45.94
- IOBT 49.82
- Support Level
- CEE $14.94
- IOBT $1.20
- Resistance Level
- CEE $15.49
- IOBT $1.57
- Average True Range (ATR)
- CEE 0.34
- IOBT 0.15
- MACD
- CEE -0.07
- IOBT -0.03
- Stochastic Oscillator
- CEE 23.03
- IOBT 22.33
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.